AFP.AU Aft Pharmaceuticals Ltd
- Market cap
- AUD 380M
- P/E
- 30.2x
- P/B
- 4.31x
- ROE
- 13.4%
- Dividend yield
- 0.37%
- Fundamental score
- 2.7/5
Ratios use the latest price and the fiscal year ending Mar 2026.
Is AFP.AU undervalued?
Graham numberAFP.AU trades 140.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aft Pharmaceuticals Ltd fundamental analysis
13 of 22 checks passedROE 1/2
Moderate return on equity (13.4%), between 10% and 20%.
ROA 1/1
Return on assets (6.8%) is above the industry median (-8.9%).
Profit Consistency 2/2
Profitable for 7 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (24.0%) is above the 5-year average (13.8% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (24.0%) is below the industry median (42.8%).
Revenue Growth 2/2
Revenue grew 17.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (49.1%), up to 100%.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 1/1
EBIT is 10.0x against interest expense, well covered.
PE vs Market 0/1
PE (30.2x) is above the market median (15.0x).
PE vs Industry 0/1
PE (30.2x) is above the industry median (21.9x).
PBV 0/1
Price to book (4.3x) is above the industry median (2.0x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 130.2, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 2.19, above 1.
Dividend Yield 0/2
Dividend yield (0.4%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 12.8%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Aft Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aft Pharmaceuticals Ltd
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a …
Full company profileAft Pharmaceuticals Ltd financial statements
Aft Pharmaceuticals Ltd annual financial statements (NZD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 69.2M | 81.2M | 85.1M | 106M | 113M | 130M | 157M | 194M | 205M | 257M |
| Gross Profit | 26.0M | 35.3M | 40.7M | 48.3M | 48.7M | 61.8M | 73.0M | 86.9M | 89.2M | 111M |
| Operating Income | -14.9M | -8.65M | 6.64M | 11.5M | 10.7M | 20.4M | 19.7M | 20.3M | 11.7M | 25.0M |
| EBITDA | -14.1M | -9.67M | 6.49M | 22.1M | 12.4M | 22.1M | 20.4M | 27.7M | 21.5M | 28.8M |
| Net Income | -18.4M | -13.6M | -3.36M | 12.7M | 7.78M | 19.8M | 10.7M | 15.6M | 12.0M | 14.8M |
| EPS | -0.18 | -0.14 | -0.03 | 0.12 | 0.07 | 0.19 | 0.10 | 0.15 | 0.11 | 0.14 |
| Balance Sheet | ||||||||||
| Total Assets | 58.3M | 56.6M | 63.6M | 87.1M | 105M | 127M | 148M | 165M | 170M | 219M |
| Total Liabilities | 38.9M | 49.3M | 58.5M | 69.8M | 68.5M | 65.0M | 74.8M | 77.5M | 72.7M | 109M |
| Shareholders' Equity | 19.5M | 7.34M | 5.09M | 17.3M | 36.6M | 62.3M | 73.3M | 87.8M | 97.6M | 111M |
| Cash & Short-term Investments | 15.9M | 6.77M | 6.92M | 6.12M | 3.21M | 7.94M | 4.75M | 12.0M | 11.1M | 10.3M |
| Total Debt | 23.4M | 30.7M | 41.8M | 47.2M | 42.2M | 40.5M | 38.0M | 32.2M | 30.0M | 54.5M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -19.1M | -9.17M | 1.07M | 14.9M | 750K | 14.2M | 11.6M | 28.9M | 13.2M | -11.8M |
| Capital Expenditure | 122K | 70.0K | 140K | 6.56M | 6.23M | 329K | 197K | 9.53M | 6.95M | 117K |
| Free Cash Flow | -19.2M | -9.24M | 927K | 8.32M | -5.48M | 13.8M | 11.4M | 19.3M | 6.23M | -12.0M |
| Ratios | ||||||||||
| ROE | -94.4% | -185.5% | -66.0% | 73.6% | 21.3% | 31.9% | 14.5% | 17.8% | 12.3% | 13.4% |
| ROA | -31.5% | -24.1% | -5.3% | 14.6% | 7.4% | 15.6% | 7.2% | 9.4% | 7.0% | 6.8% |
| Net Profit Margin | -26.6% | -16.8% | -3.9% | 12.0% | 6.9% | 15.2% | 6.8% | 8.0% | 5.8% | 5.8% |
| Debt to Equity | 1.20x | 4.18x | 8.20x | 2.74x | 1.15x | 0.65x | 0.52x | 0.37x | 0.31x | 0.49x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aft Pharmaceuticals Ltd dividends
- Dividend yield
- 0.37%
- Forward dividend
- 0.01 AUD
- Payout ratio
- 12.8%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | NZD 1.90M | 0.02 | 12.8% |
| 2025 | NZD 1.68M | 0.02 | 14.0% |
| 2024 | NZD 1.15M | 0.01 | 7.4% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | NZD 188K | 0.00 | 2.4% |
| 2020 | NZD 566K | 0.01 | 4.5% |
| 2019 | NZD 134K | 0.00 | - |
| 2018 | NZD 412K | 0.00 | - |
| 2017 | NZD 412K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Aft Pharmaceuticals Ltd
- Insiders 77.64%
- Institutions 1.26%
- Public & others 21.11%
- Shares outstanding 105M
- Free float 30.4M
Top funds holding AFP.AU
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Commonwealth International Ser-Australia/New Zealand Fund | 46.0K | 0.04% | - | Feb 2021 |
Aft Pharmaceuticals Ltd company profile
- Company name
- Aft Pharmaceuticals Ltd
- Ticker
- AFP.AU
- ISIN
- NZAFTE0001S4
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 126
- Fiscal year end
- March
- Address
- 129 Hurstmere Road, Auckland, New Zealand, 0622
- Phone
- 64 8 0042 3823
- Website
- aftpharm.com
About Aft Pharmaceuticals Ltd
AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.
Aft Pharmaceuticals Ltd management
5- Dr. Hartley Atkinson Ph.D.Co-Founder, CEO, MD & Executive Director
- Ms. Marree AtkinsonCo-Founder, Chief of Staff & Executive Director
- Mr. Stuart D. HoulistonChief Financial Officer
- Ms. Ioana StanescuChief Scientific Officer
- Mr. Murray KeithGroup Marketing Manager